The Malarial Treatment of General Paralysis [A Summary of Gerstmann's Monograph based on the work of the Vienna Psychiatric Clinic]. (State Hosp. Quarterly, August, 1926.) Fiertz, C. O.

1927 ◽  
Vol 73 (301) ◽  
pp. 327-327
Author(s):  
G. de M. Rudolf
Keyword(s):  
Psychiatric Clinic ◽  
General Paralysis

The Malarial Treatment of General Paralysis.

1925 ◽  
Vol 71 (294) ◽  
pp. 424-431 ◽  
Author(s):  
Norman B. Graham
Keyword(s):  
Psychiatric Clinic ◽  
General Paralysis

When in the year 1917 Dr. Wagner-Jauregg, Chief of the Psychiatric Clinic of Vienna, inoculated nine patients suffering from general paralysis with the blood of a case of benign tertian malaria, he was only testing a theory he had formed many years previously. In the interval he had been treating his cases of general paralysis by injections of tuberculin, typhus vaccine, etc., and with encouraging results. Remissions produced by these efforts were more frequent and more lasting than those which occurred in untreated cases, but a lasting remission only rarely followed.

Malaria therapy in Spain: 100 years after its introduction as a treatment for the general paralysis of the insane

2020 ◽  
Vol 31 (3) ◽  
pp. 325-340
Author(s):  
Olga Villasante
Keyword(s):  
Mental Hospital ◽  
Rockefeller Foundation ◽  
Psychiatric Clinic ◽  
San Jose ◽  
General Paralysis ◽  
Malaria Therapy ◽  
Psychiatric Institutions ◽  
Fever Therapy ◽  
The Military

This article addresses the implementation of malaria fever therapy in Spain. Neuropsychiatrist Rodríguez-Lafora first used it in 1924, but Vallejo-Nágera was the main advocate for the technique. He had learned the method from Wagner von Jauregg himself, and he worked in the Military Psychiatric Clinic and the San José Mental Hospital, both in Ciempozuelos (Madrid). Vallejo-Nágera worked with the parasitologist Zozaya, who had travelled to England with a Rockefeller Foundation grant in order to learn from British malariologist, Sydney Price James. This article details the results of the uneven implementation of this treatment in Spanish psychiatric institutions. Although syphilologists and internists used fever therapy for the treatment of general paralysis of the insane, they were much less enthusiastic than psychiatrists.

The role of personality traits in initiating and maintaining addictive behavior

2016 ◽  
Vol 33 (S1) ◽  
pp. S307-S307
Author(s):  
M. Manea ◽  
B. Savu
Keyword(s):  
Substance Abuse ◽  
Anxiety Disorders ◽  
Personality Traits ◽  
Trait Anxiety ◽  
Psychiatric Clinic ◽  
Strongly Correlated ◽  
Addictive Disorder ◽  
Substance Disorders ◽  
Competing Interest

IntroductionIt is well known that certain personality traits are more linked to drug abuse than others. Psychiatrists are more likely to emphasize the importance of impulsivity in the connection with substance disorders but in the following study we found an important percentage of patients that have a substance abuse were linked to anxiety through impulsiveness as a personality trait.ObjectivesMost youths admitted for a substance abuse are highly impulsive. Our quest was to differentiate what component of impulsivity was more frequently linked to a substance use disorder.MethodsIn the study were included 50 patients admitted in the 3rd Psychiatric Clinic, Substance Dependences Department, Cluj-Napoca. For the identification of the drug abused we used the multitest screening kit in correlation with the results from the Forensic Medicine Institute of Cluj-Napoca. Each patient completed the Barratt Impulsivity Scale and the Swedish Universities Scales of Personality.ResultsHigh scores on BIS-11 strongly correlated with attentional impulsiveness (Pearson's r correlation = .838) which means high inattention and cognitive instability this being linked with anxiety disorders. Cognitive Instability was correlated with Psychic Trait Anxiety (r = 0.29) and Motor Impulsiveness with Somatic Trait Anxiety (r = 0.3). Normal 0 false false false EN-US X-NONE X-NONE.ConclusionsThe underrecognized anxiety disorders in young adults whom are admitted for an addictive disorder prefrontal cortex is known to be the source of both impulsivity and could be linked to anxiety as well (valence asymmetry hypothesis). Normal 0 false false false EN-US X-NONE X-NONE.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals A Repeated Time-to-Positive Symptoms Improvement among Malaysian Patients with Schizophrenia Spectrum Disorders Treated with Clozapine

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1121
Author(s):  
Orwa Albitar ◽  
Sabariah Noor Harun ◽  
Siti Nor Aizah Ahmad ◽  
Siti Maisharah Sheikh Ghadzi
Keyword(s):  
Visual Predictive Check ◽  
Clinical Importance ◽  
Antipsychotic Agent ◽  
Survival Models ◽  
Psychiatric Clinic ◽  
Positive Symptoms ◽  
Schizophrenia Spectrum Disorders ◽  
Mixed Effect ◽  
Essential Information ◽  
Schizophrenia Spectrum

Clozapine remains the drug of choice for resistant schizophrenia. However, its dose-response relationship is still controversial. The current investigation aimed to develop a repeated time-to-positive symptoms improvement following the onset of clozapine treatment in Malaysian schizophrenia spectrum disorder patients. Data from patients’ medical records in the Psychiatric Clinic, Penang General Hospital, were retrospectively analyzed. Several parametric survival models were evaluated using nonlinear mixed-effect modeling software (NONMEM 7.3.0). Kaplan–Meier-visual predictive check (KM-VPC) and sampling-importance resampling (SIR) methods were used to validate the final model. A total of 116 patients were included in the study, with a mean follow-up of 306 weeks. Weibull hazard function best fitted the data. The hazard of positive symptoms improvement decreased 4% for every one-year increase in age over the median of 41 years (adjusted hazard ratio (aHR), 0.96; 95% confidence intervals (95% CI), (0.93–0.98)). However, patients receiving a second atypical antipsychotic agent had four-folds higher hazard (aHR, 4.01; 95% CI, (1.97–7.17)). The hazard increased 2% (aHR, 1.02; 95% CI, (1.01–1.03)) for every 1 g increase in the clozapine six months cumulative dose over the median of 34 g. The developed model provides essential information on the hazard of positive symptoms improvement after the first clozapine dose administration, including modifiable predictors of high clinical importance.

Sign in / Sign up

Export Citation Format

Share Document